Related references
Note: Only part of the references are listed.Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
Gordon J. S. Rustin et al.
LANCET (2010)
Multiple imputation in a large-scale complex survey: a practical guide
Y. He et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2010)
The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer
H. Oksefjell et al.
ANNALS OF ONCOLOGY (2009)
Missing Data Analysis: Making It Work in the Real World
John W. Graham
ANNUAL REVIEW OF PSYCHOLOGY (2009)
Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO)
Andreas du Bois et al.
CANCER (2009)
Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: A phase II study
Patti Power et al.
GYNECOLOGIC ONCOLOGY (2009)
Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis
Robert E. Bristow et al.
GYNECOLOGIC ONCOLOGY (2009)
Use of multiple imputation in the epidemiologic literature
Mark A. Klebanoff et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2008)
Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200)
David S. Alberts et al.
GYNECOLOGIC ONCOLOGY (2008)
Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: Results of a phase III study of the North-Eastern German Society of Gynecological Oncology ovarian cancer study group
Jalid Sehouli et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer - Analysis of prognostic factors and survival outcome
Ritu Salani et al.
CANCER (2007)
Surgery in recurrent ovarian cancer:: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial
Philipp Harter et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer:: An intergroup trial of the AGO-OVAR, the NCICCTG, and the EORTC GCG
Jacobus Pfisterer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma
DS Chi et al.
CANCER (2006)
Optimal cut-point and its corresponding youden index to discriminate individuals using pooled blood samples
EF Schisterman et al.
EPIDEMIOLOGY (2005)
Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: Who benefits?
RY Zang et al.
CANCER (2004)
Share Paper
